Table 3.

Flagellin-specific immunoglobulins in SBS patients and control subjects

	Baseline	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24
SBS IgM	1.45±0.19*	1.22±0.14	1.31±0.14	1.27±0.16	1.29±0.15	1.28±0.13	1.29±0.15
Healthy control IgM	0.60±0.05
ICU control IgM	0.36±0.41
SBS IgA	0.16±0.03*	0.15±0.02	0.16±0.02	0.14±0.02	0.16±0.02	0.15±0.02	0.17±0.03
Healthy control IgA	0.04±0.01
ICU control IgA	0.05±0.03
SBS IgG	0.26±0.04*	0.20±0.02	0.23±0.03	0.21±0.03	0.21±0.02	0.22±0.03	0.24±0.03
Healthy control IgG	0.07±0.01
ICU control IgG	0.05±0.04

Data are means ± SE, expressed as optical density readings.

^*P ≤ 0.001, SBS (n = 23) vs. control subjects (n = 48) and critically ill patients without SBS requiring parenteral nutrition (n = 37). SBS patients have short bowel syndrome; controls are healthy subjects with intact intestine; ICU controls are adults without SBS requiring PN following cardiac, vascular, or colonic surgery in the surgical intensive care unit.